# A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung

Source: https://onco.cc/trials/nct05085028/  
OnCo record `nct05085028` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Imperial College London, now recruiting.

## Summary

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 3, randomised interventional study registered as NCT05085028 by Imperial College London, with a registry enrolment figure of 1750 participants, started 2022-06-23 and due to reach its primary completion in 2027-05-31. Interventions recorded: Pembrolizumab 25 MG/ML [Keytruda]. Conditions listed: Lung Cancer, Nonsmall Cell. Primary outcome: Overall survival at 2 years. Lung eligibility wording from the registry: "* Any patient ≥18yrs who has received 6 months of pembrolizumab treatment with or without chemotherapy for advanced Non small cell lung cancer who is planned to continue immunotherapy treatment because of continued benefit". Sites: United Kingdom. United Kingdom sites listed: 37. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: REFINE-Lung
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05085028
- Phase: 3
- Setting: A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Utilising a Novel Multi-arm Frequency-response Optimisation Design
- Sponsor: Imperial College London
- Enrolled: 1750

## Notes

- UK sites (registry): Royal Bournemouth Hospital (Bournemouth); Royal Sussex County Hospital (Brighton); Bristol Haematology and Oncology Centre (Bristol); Queen's Hospital (Burton-on-Trent); Cambridge University Hospitals NHS Foundation Trust (Cambridge); East Kent Hospitals University NHS Foundation Trust (Canterbury); Velindre Cancer Centre (Cardiff); Colchester Hospital (Colchester); Royal Derby Hospital (Derby); NHS Lothian (Edinburgh); Royal Devon and Exeter Hospital (Exeter); Beatson West of Scotland Cancer Centre (Glasgow) and 25 more.

## Sources

- ClinicalTrials.gov NCT05085028: https://clinicaltrials.gov/study/NCT05085028

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05085028.json